{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:20:52Z","timestamp":1784996452702,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T00:00:00Z","timestamp":1469577600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Promotive Research Fund for Science and Technology Development Plan Project of Yantai, Shandong Province","award":["No. 2013WS209"],"award-info":[{"award-number":["No. 2013WS209"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s11255-016-1379-8","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T07:22:46Z","timestamp":1469604166000},"page":"2043-2050","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4"],"prefix":"10.1007","volume":"48","author":[{"given":"Wei","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengqiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bofeng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,27]]},"reference":[{"key":"1379_CR1","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1093\/ndt\/gfq582","volume":"26","author":"M Noordzij","year":"2011","unstructured":"Noordzij M, Cranenburg EM, Engelsman LF, Hermans MM, Boeschoten EW, Brandenburg VM, Bos WJ, Kooman JP, Dekker FW, Ketteler M, Schurgers LJ, Krediet RT, Korevaar JC, NECOSAD Study Group (2011) Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients. Nephrol Dial Transplant 26:1662\u20131669","journal-title":"Nephrol Dial Transplant"},{"key":"1379_CR2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","volume":"52","author":"F Tentori","year":"2008","unstructured":"Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK (2008) Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52:519\u2013530","journal-title":"Am J Kidney Dis"},{"key":"1379_CR3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","volume":"6","author":"J Cunningham","year":"2011","unstructured":"Cunningham J, Locatelli F, Rodriguez M (2011) Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6:913\u2013921","journal-title":"Clin J Am Soc Nephrol"},{"key":"1379_CR4","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","volume":"16","author":"B Kestenbaum","year":"2005","unstructured":"Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL (2005) Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16:520\u2013528","journal-title":"J Am Soc Nephrol"},{"key":"1379_CR5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/ndt\/gfi236","volume":"21","author":"M Sigrist","year":"2006","unstructured":"Sigrist M, Bungay P, Taal MW, McIntyre CW (2006) Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant 21:707\u2013714","journal-title":"Nephrol Dial Transplant"},{"key":"1379_CR6","doi-asserted-by":"crossref","first-page":"360","DOI":"10.5414\/CNP73360","volume":"73","author":"Y Sumida","year":"2010","unstructured":"Sumida Y, Nakayama M, Nagata M, Nakashita S, Suehiro T, Kaizu Y, Ikeda H, Izumaru K (2010) Carotid artery calcification and atherosclerosis at the initiation of hemodialysis in patients with end-stage renal disease. Clin Nephrol 73:360\u2013369","journal-title":"Clin Nephrol"},{"key":"1379_CR7","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/ndt\/gfg414","volume":"18","author":"GM London","year":"2003","unstructured":"London GM, Guerin AP, Marchais SJ, M\u00e9tivier F, Pannier B, Adda H (2003) Arterial media calcification in endstage renal diseases: impact on all cause and cardiovascular mortality. Nephrol Dial Transplant 18:1731\u20131740","journal-title":"Nephrol Dial Transplant"},{"key":"1379_CR8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1681\/ASN.2008040349","volume":"20","author":"KL Adeney","year":"2009","unstructured":"Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, Kestenbaum BR (2009) Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 20:381\u2013387","journal-title":"J Am Soc Nephrol"},{"key":"1379_CR9","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1111\/j.1523-1755.2005.00333.x","volume":"67","author":"SM Moe","year":"2005","unstructured":"Moe SM, Reslerova M, Ketteler M, O\u2019Neill K, Duan D, Koczman J, Westenfeld R, Jahnen-Dechent W, Chen NX (2005) Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 67:2295\u20132304","journal-title":"Kidney Int"},{"key":"1379_CR10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2369-14-22","volume":"14","author":"M Nakayama","year":"2013","unstructured":"Nakayama M, Kaizu Y, Nagata M, Ura Y, Ikeda H, Shimamoto S, Kuma K (2013) Fibroblast growth factor 23 is associated with carotid artery calcification in chronic kidney disease patients not undergoing dialysis: a cross-sectional study. BMC Nephrol 14:22","journal-title":"BMC Nephrol"},{"key":"1379_CR11","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/jbmr.1630","volume":"27","author":"Y Sabbagh","year":"2012","unstructured":"Sabbagh Y, Graciolli FG, O\u2019Brien S, Tang W, dos Reis LM, Ryan S, Phillips L, Boulanger J, Song W, Bracken C, Liu S, Ledbetter S, Dechow P, Canziani ME, Carvalho AB, Jorgetti V, Moyses RM, Schiavi SC (2012) Repression of osteocyte Wnt\/\u03b2-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 27:1757\u20131772","journal-title":"J Bone Miner Res"},{"key":"1379_CR12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1210\/jc.2013-2786","volume":"99","author":"D Cejka","year":"2014","unstructured":"Cejka D, Marculescu R, Kozakowski N (2014) Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 99:248\u2013255","journal-title":"J Clin Endocrinol Metab"},{"key":"1379_CR13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00223-010-9372-1","volume":"87","author":"MJ Moester","year":"2010","unstructured":"Moester MJ, Papapoulos SE, L\u00f6wik CW, van Bezooijen RL (2010) Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 87:99\u2013107","journal-title":"Calcif Tissue Int"},{"key":"1379_CR14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/1471-2369-14-219","volume":"14","author":"VM Brandenburg","year":"2013","unstructured":"Brandenburg VM, Kramann R, Koos R, Kr\u00fcger T, Schurgers L, M\u00fchlenbruch G, H\u00fcbner S, Gladziwa U, Drechsler C, Ketteler M (2013) Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol 14:219","journal-title":"BMC Nephrol"},{"key":"1379_CR15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461\u2013470","journal-title":"Ann Intern Med"},{"key":"1379_CR16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/ndt\/gfv081","volume":"30","author":"M Morena","year":"2015","unstructured":"Morena M, Jaussent I, Dupuy AM, Bargnoux AS, Kuster N, Chenine L, Leray-Moragues H, Klouche K, Vernhet H, Canaud B, Cristol JP (2015) Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant 30:1345\u20131356","journal-title":"Nephrol Dial Transplant"},{"key":"1379_CR17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2215\/CJN.07670712","volume":"8","author":"S Pelletier","year":"2013","unstructured":"Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D (2013) The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 8:819\u2013823","journal-title":"Clin J Am Soc Nephrol"},{"key":"1379_CR18","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.2215\/CJN.04331206","volume":"3","author":"SM Moe","year":"2008","unstructured":"Moe SM, Dr\u00fceke T (2008) Improving global outcomes in mineral and bone disorders. Clin J Am Soc Nephrol 3:S127\u2013S130","journal-title":"Clin J Am Soc Nephrol"},{"key":"1379_CR19","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/ndt\/gfl718","volume":"22","author":"L Craver","year":"2007","unstructured":"Craver L, Marco MP, Mart\u00ednez I, Rue M, Borr\u00e0s M, Mart\u00edn ML, Sarr\u00f3 F, Valdivielso JM, Fern\u00e1ndez E (2007) Mineral metabolism parameters throughout chronic kidney disease stages 1\u20135\u2014achievement of K\/DOQI target ranges. Nephrol Dial Transplant 22:1171\u20131176","journal-title":"Nephrol Dial Transplant"},{"key":"1379_CR20","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1161\/CIRCRESAHA.110.234914","volume":"109","author":"CM Shanahan","year":"2011","unstructured":"Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM (2011) Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 109:697\u2013711","journal-title":"Circ Res"},{"key":"1379_CR21","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1093\/ndt\/gfr591","volume":"26","author":"JB Cannata-Andia","year":"2011","unstructured":"Cannata-Andia JB, Roman-Garcia P, Hruska K (2011) The connections between vascular calcification and bone health. Nephrol Dial Transplant 26:3429\u20133436","journal-title":"Nephrol Dial Transplant"},{"key":"1379_CR22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00223-012-9595-4","volume":"90","author":"S Thambiah","year":"2012","unstructured":"Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D, Hampson G (2012) Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 90:473\u2013480","journal-title":"Calcif Tissue Int"},{"key":"1379_CR23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/jbmr.217","volume":"26","author":"UI M\u00f6dder","year":"2011","unstructured":"M\u00f6dder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ 3rd, Khosla S (2011) Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 26:373\u2013379","journal-title":"J Bone Miner Res"},{"key":"1379_CR24","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI28551","volume":"116","author":"V Krishnan","year":"2006","unstructured":"Krishnan V, Bryant HU, Macdougald OA (2006) Regulation of bone mass by Wnt signaling. J Clin Invest 116:1202\u20131209","journal-title":"J Clin Invest"},{"key":"1379_CR25","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2215\/CJN.01370211","volume":"6","author":"TB Dr\u00fceke","year":"2011","unstructured":"Dr\u00fceke TB, Lafage-Proust MH (2011) Sclerostin: just one more player in renal bone disease? Clin J Am Soc Nephrol 6:700\u2013703","journal-title":"Clin J Am Soc Nephrol"},{"key":"1379_CR26","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","volume":"19","author":"KE Poole","year":"2005","unstructured":"Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, L\u00f6wik CW, Reeve J (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842\u20131844","journal-title":"FASEB J"},{"key":"1379_CR27","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2215\/CJN.06550810","volume":"6","author":"D Cejka","year":"2011","unstructured":"Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH (2011) Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 6:877\u2013882","journal-title":"Clin J Am Soc Nephrol"},{"key":"1379_CR28","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1093\/ndt\/gft039","volume":"28","author":"L Viaene","year":"2013","unstructured":"Viaene L, Behets GJ, Claes K, Meijers B, Blocki F, Brandenburg V, Evenepoel P, D\u2019Haese PC (2013) Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant 28:3024\u20133030","journal-title":"Nephrol Dial Transplant"},{"key":"1379_CR29","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.2337\/dc12-1691","volume":"36","author":"S Morales-Santana","year":"2013","unstructured":"Morales-Santana S, Garc\u00eda-Fontana B, Garc\u00eda-Mart\u00edn A, Rozas-Moreno P, Garc\u00eda-Salcedo JA, Reyes-Garc\u00eda R, Mu\u00f1oz-Torres M (2013) Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care 36:1667\u20131674","journal-title":"Diabetes Care"},{"key":"1379_CR30","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1210\/jc.2013-1521","volume":"98","author":"KJ Claes","year":"2013","unstructured":"Claes KJ, Viaene L, Heye S, Meijers B, d\u2019Haese P, Evenepoel P (2013) Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab 98:3221\u20133228","journal-title":"J Clin Endocrinol Metab"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-016-1379-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-016-1379-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-016-1379-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T19:26:01Z","timestamp":1568229961000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-016-1379-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,27]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1379"],"URL":"https:\/\/doi.org\/10.1007\/s11255-016-1379-8","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,27]]}}}